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A wide range of molecules acting as apoptotic cell-associated ligands, phagocyte-associated receptors or soluble bridging
molecules have been implicated within the complex sequential processes that result in phagocytosis and degradation of
apoptotic cells. Intercellular adhesion molecule 3 (ICAM-3, also known as CD50), a human leukocyte-restricted immunoglobulin
super-family(IgSF)member,haspreviouslybeenimplicatedinapoptoticcellclearance,althoughitspreciseroleintheclearance
process is ill deﬁned. Themain objectiveof thiswork is tofurther characterise the function ofICAM-3 inthe removal of apoptotic
cells.Usingarangeofnovelanti-ICAM-3monoclonalantibodies(mAbs),includingone(MA4)thatblocksapoptoticcellclearance
by macrophages, alongside apoptotic human leukocytes that are normal or deﬁcient for ICAM-3, we demonstrate that ICAM-3
promotesadomain1–2-dependenttetheringinteractionwithphagocytes.Furthermore,wedemonstrateanapoptosis-associated
reduction in ICAM-3 that results from release of ICAM-3 within microparticles that potently attract macrophages to apoptotic
cells. Taken together, these data suggest that apoptotic cell-derived microparticles bearing ICAM-3 promote macrophage
chemoattractiontositesofleukocytecelldeathandthatICAM-3mediatessubsequentcellcorpsetetheringtomacrophages.The
deﬁned function of ICAM-3 in these processes and profound defect in chemotaxis noted to ICAM-3-deﬁcient microparticles
suggest that ICAM-3 may be an important adhesion molecule involved in chemotaxis to apoptotic human leukocytes.
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Cells undergoing programmed cell death (apoptosis) are
efﬁciently removed by phagocytes in a process important for
development, tissue maintenance and control of immune
responses. Whereas neighbouring viable cells may remove
low levels of local cell death, professional recruited macro-
phages deal with high levels of apoptotic death. Failure to
effectively clear dying cells has been implicated in a range of
pathological scenarios.
1–3
The molecular mechanisms that underlie phagocyte re-
cognition and clearance of apoptotic cells are still under
investigation, although a wide range of phagocyte receptors
andamorelimitednumberofapoptoticcell-surfacemolecules
have been deﬁned.
2,4 These molecules participate in a
multistage process that, at least in the case of recruited
professional phagocytes, involves recruitment through che-
motaxis
5–8 before apoptotic cell recognition, tethering and
phagocytosis, all of which are accompanied by immunomo-
dulatorysignalling.Themostwidely establishedchangeatthe
apoptotic cell surface is exposure of the aminophospholipid
phosphatidylserine (PS) that mediates clearance.
9–11 How-
ever, other less well-deﬁned changes indicate an involvement
of sugars,
12–14, PS oxidation
15 and exposure of intracellular
components (e.g., annexin I).
16 Previous work suggested that
the immunoglobulin super-family (IgSF) member intercellular-
adhesion molecule (ICAM)-3, expressed on human leuko-
cytes, becomes functionally altered during apoptosis to
mediate clearance of apoptotic leukocytes through suggested
generation of neo-epitopes (i.e., ‘eat me’ signals).
17 However,
more recently, a study of CD31, another IgSF member,
suggests that molecules on viable cells may provide inhibitory
signals
18 that are lost during apoptosis, permitting viable
cellular interactions (e.g., CD31–CD31 in trans) to become
functional phagocytic interactions.
18–20 CD47 may also
mediate such inhibitory signals.
21–23 It seems likely that loss
of inhibitory signals and gain of neo-epitopes occur at the
apoptotic cell surface and together facilitate cell removal.
However, the role and nature of apoptotic cell-associated
ICAM-3 in the multistep process of apoptotic cell clearance
have remained elusive.
Here we show apoptotic cell-associated ICAM-3 functions
in tethering apoptotic cells to phagocytes. However, during
apoptosis it is known that levels of surface proteins may be
reduced through loss of membrane into apoptotic bodies
(microparticles).
24 Such microparticles from apoptotic B cells
havebeen showntohavestrongchemoattractive properties
24
in a manner dependent upon the chemokine fractalkine
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www.nature.com/cdd(CX3CL1), which acts as a ‘ﬁnd me’ signal, and its cognate
receptor (CX3CR1).
25 Here we show that rapid and sub-
stantial loss of ICAM-3 from the surface of apoptotic
leukocytes occurs via microparticle shedding and these
microparticles are strongly chemoattractive in a manner
dependent upon ICAM-3. Together with the established role
of ICAM-3 as an important adhesion molecule involved in
immune synapse formation, our data provide new insight into
the mechanisms of chemoattraction of phagocytes to apopto-
tic cells and identify ICAM-3 as a key adhesion molecule
within the process.
Results
Interaction of apoptotic cells with phagocytes is inhi-
bited by ICAM-3 mAb MA4. Moffatt et al.
17 characterised
two, now unavailable, anti-ICAM-3 monoclonal antibodies
(mAbs: BU68 and 3A9) capable of blocking interaction of
apoptotic cells with phagocytes showing that they were
reactive to the membrane-distal domains of ICAM-3
(domains 1 and 2). Here a panel of novel mAbs raised
from mice immunised with ICAM-3-transfected human
embryonic kidney (HEK) cells were screened by ELISA
against recombinant ICAM-3 (domains 1 and 2)-Fc fusion
protein and CD14-Fc as a control (Supplementary Figure 1).
We identiﬁed 17 anti-ICAM-3 mAbs speciﬁc for domains 1
and 2.
Using an established model system of speciﬁc apoptotic
cell clearance,
26,27 wescreened theseanti-ICAM-3 mAbsand
identiﬁed one, MA4, that robustly inhibited apoptotic cell
interaction with phagocytes (Figures 1a and b). The observed
degree of inhibition with MA4 (59±14%) was in line with that
seen previously with ICAM-3 mAbs BU68 and 3A9.
17 Other
mAbs (e.g., BH10 and GD12) of the same isotype (murine
IgG1/k) were also screened but failed to inhibit clearance.
FurtheranalysesindicatedthatMA4,BH10andGD12wereall
capable of reacting with full-length ICAM-3 (domains 15) that
was denatured and reduced (assessed by western blotting) or
native and cell-associated ICAM-3 (assessed by ﬂow cyto-
metry) (Supplementary Figure 1).
These results conﬁrm MA4 as a novel anti-ICAM-3 mAb
thatreactswithaprobablelinearepitopeindomains1and2of
ICAM-3, and is capable of inhibiting apoptotic cell interaction
with phagocytes.
Apoptotic cells deﬁcient for ICAM-3 exhibit reduced
clearance by phagocytes. Earlier studies showed that the
role of ICAM-3 on apoptotic cells in promoting clearance can
be revealed through the use of inhibitory mAbs (Figure 1a,
and see Moffatt et al.
17) and by overexpression of ICAM-3 to
promote clearance.
17 Here we demonstrate an alternative
and complementary method to reveal a role for ICAM-3 in
apoptotic cell clearance. ICAM-3-deﬁcient Mutu Burkitt’s
lymphoma (BL) cells or Jurkat T cells (human leukocyte
cell lines that normally express ICAM-3) were isolated
following sequential ﬂow cytometric sorting for very low/
negative expression levels of surface ICAM-3. The cellular
proteome analysed by 2D gel electrophoresis
28 was not
signiﬁcantly different between ICAM-3-deﬁcient cells and
their ICAM-3-replete counterparts. Such ICAM-3-deﬁcient
cells exhibited reduced ability to interact with THP-1 phago-
cytes when compared with their ICAM-3-replete counterparts
(Figure 2a). Similar results were noted with primary human
monocyte-derived macrophages (Supplementary Figure 2).
Detailed analysis of apoptotic cell death indicated that both
populations of cells died with the same kinetics and to
the same extent irrespective of their ICAM-3 expression
(Supplementary Figure 3). Furthermore, when apoptotic cells
were incubated with phagocytes in the presence of MA4, only
the recognition of ICAM-3-expressing cells was inhibited
Figure 1 Inhibition of apoptotic cell interaction with THP-1 phagocytes by anti-
ICAM-3mAbMA4.(a)MutuBLcellswereinducedtoapoptosisbyUV(100mJ/cm
2)
and co-cultured with THP-1 phagocytes (MØ) in the presence of the indicated
mAbs. The proportion of MØ interacting with (tethering and/or phagocytosing)
apoptotic cells (ACs) was scored using light microscopy following Jenner/Giemsa
staining. Data (mean±S.D.) from at least three separate experiments each carried
out in quadruplicate are shown (data are normalised to the mAb-free co-culture
(‘Alone’). (b) Microscopic appearance of a THP-1 phagocyte culture or co-cultures
ofTHP-1 andACsinthepresenceorabsenceoftheindicatedmAb(MA4or BH10).
Scale bar¼50mm. **Po0.01 ANOVA with Dunnett’s post-hoc test
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Cell Death and Differentiation(Figure 2c and d), supporting the speciﬁcity of effect by MA4.
This phenomenon was evident irrespective of the method
chosen for induction of apoptosis (UV (Figure 2), ionomycin
or staurosporine (data not shown)).
It is notable that ICAM-3 mediates apoptotic human
leukocyte clearance by murine macrophages (Figure 2d).
These data demonstrate that the phagocyte receptor function
for apoptotic ICAM-3 is present in mice where ICAM-3 is
naturally absent. Taken together, these data further demon-
strate a role for ICAM-3 in the interaction of apoptotic
leukocytes with phagocytes, consistent with our previous
reports, and that the receptor for apoptotic ICAM-3 likely
recognises molecular changes that may not be restricted to
ICAM-3.Indeed,theseobservationsfurthersupportthenotion
that clearance mechanisms are highly conserved across
species.
Apoptotic cell-associated ICAM-3 mediates tethering to
phagocytes. The phagocytic removal of apoptotic cells is a
complex multistep process.
2 To address whether apoptotic
cell-associated ICAM-3 functions as a ligand for tethering or
engulfment, apoptotic leukocytes were co-cultured with phago-
cytes at 201C, permissive only for apoptotic cell tethering
to phagocytes,
29 and results were compared with assays at
371C, permissive for both tethering and phagocytosis. Here
we show reduced tethering of ICAM-3-deﬁcient BL cells with
human phagocytes when compared with their ICAM-3-replete
counterparts (Figure 3a). These data strongly implicate ICAM-3
as a tethering ligand for apoptotic cells, a function also demon-
strated using mouse macrophages (Figure 3b).
ICAM-3 levels reduce during apoptosis due to shedding
in microparticles. It is intriguing that ICAM-3 levels reduce
during apoptosis given the emergence of a role for ICAM-3 in
apoptotic cells.
17 Mutu B cells provide a robust model for the
analysis of early apoptosis by ﬂow cytometry. Light scatter
(forward scatter/electronic volume (FS/EV) versus side scatter
(SS)) deﬁnes two cell populations (Figure 4a): region 1: smaller
and more granular cells that are necrotic (including late
apoptotic/secondary necrotic cells) and stain with the vital
dye propidium iodide (PI); and region 2: larger and
less granular cells (live or early apoptotic) where plasma
membranes are intact and exclude PI.
27,30 Region 2 cells
(live/early apoptotic) are therefore viable or actively
undergoing apoptosis (as detected by annexin V (AxV)
staining and exclusion of PI). This live/early apoptotic region
Figure 2 Interaction of apoptotic cells with human or mouse phagocytes is reduced in the absence of apoptotic ICAM-3. WT and ICAM-3-deﬁcient BL and Jurkat cells
wereinducedtoapoptosisbyUV(Mutu:100mJ/cm
2;Jurkat150mJ/cm
2)andco-culturedwithTHP-1phagocytes(MØ)for1h.TheproportionofMØinteractingwith(tethering
and/or phagocytosing) apoptotic cells (ACs) was scored using light microscopy following Jenner/Giemsa staining (a). Expression of ICAM-3 on apoptotic target cells was
assessed by indirect immunoﬂuorescence. Flow cytometric histograms of anti-ICAM-3 mAb-stained WT (grey proﬁles) or ICAM-3-deﬁcient (clear proﬁles) Mutu/BL or Jurkat
cells are shown (b). The ability of the blocking anti-ICAM-3 mAb MA4 to modulate the capacity of apoptotic WT and ICAM-3-deﬁcient BL cells to interact with THP-1
phagocytes (c) and J774 mouse phagocytes (d) was assessed. Data shown are mean±S.D. of replicate samples (n¼4) from one experiment (of at least four similar).
***Po0.001 ANOVA with Tukey’s post-hoc test
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Cell Death and Differentiationof a population of Mutu BL cells will be predominantly AxVþ/
PI  within 5–6h of UV irradiation. With continued incu-
bation, these cells change morphology to fall in region 1 (late
apoptotic/necrotic) with apoptotic nuclear morphology.
27,30
In line with previous work,
17 we noted ICAM-3 reduced (by
30%) in Mutu BL cells 24h after apoptosis induction (mean
ﬂuorescence intensity (MFI) Mutu control¼50.3 versus
Mutu 24h post UV¼35.2). No such decrease was noted
with apoptosis-resistant Mutu/B-cell lymphoma 2 (bcl-2) cells
(MFI Mutu/bcl-2 control¼50 versus Mutu/bcl-2 24h post
UV¼47.7). To exclude the effects of secondary necrosis
or prolonged incubation in vitro, ICAM-3 levels on early
apoptotic cells were further studied.
Here we demonstrate that ICAM-3 levels begin to reduce
in Mutu cells (but not Mutu/Bcl-2 cells) while still conﬁned to
the live/early apoptotic region 2, suggesting that ICAM-3
levels reduce early in apoptosis (Figure 4b) and low
ICAM-3 levels are most closely associated with PS exposure
as detected with AxV-ﬂuorescein isothiocyanate (FITC)
(Figure 4c). All cells that show low expression of ICAM-3 are
also exposing PS.
The mechanism of ICAM-3 reduction has not been
reported. A number of possible explanations for this exist
and are associated with monoclonal antibody detection of
ICAM-3. Structural alterations to ICAM-3 (e.g., changes in
glycosylation) may render mAbs unable to detect ICAM-3
even if present. Alternatively, molecular redistributions of
ICAM-3 during apoptosis may result in epitope masking such
that ICAM-3 is less detectable (via mAbs) rather than being
reduced in levels. To address this possibility, we generated a
green ﬂuorescent protein (GFP)-tagged ICAM-3 (C terminal
tag; intracellular) and expressed this in HeLa cells. These
cells showed reduced levels of ICAM-3–GFP as apoptosis
proceeded (Figure 4d), suggesting ICAM-3 loss. Together,
the reduction in GFP and concomitant loss of cell volume
(Figure 4d) suggest that ICAM-3 levels are unlikely to be
reduced simply as a result of ICAM-3 cleavage from the cell,
leaving behind the GFP tag and transmembrane domain.
Loss of ICAM-3 as an explanation of the reduced ICAM-3
levels was also supported by the observation that lymphocyte
ICAM-3 levels (detected using immunoﬂuorescent ﬂow
cytometry) also showed ICAM-3 reduced with cell volume
(Figure 4e). Apoptosis-induced reduction in cell volume is
known to occur via a number of mechanisms including
membrane loss through release of blebs to apoptotic bodies
(membrane-enclosed apoptotic cell-derived material, parti-
cles also known as microparticles).
To test the hypothesis that ICAM-3 levels reduce during
apoptosis as a result of shedding within microparticles, ICAM-
3–GFP-transfected HeLa cells were studied. Importantly,
phagocytes cleared these cells in an ICAM-3-dependent
manner (revealed by MA4 inhibition of the interaction;
Supplementary Figure 4) indicating that GFP tagging of
ICAM-3 did not disrupt the function of ICAM-3 in apoptotic cell
clearance. Detailed microscopic analyses of HeLa-ICAM-3–
GFP cells throughout an established model of apoptosis
31
revealed ICAM-3–GFP within blebs at the apoptotic cell
surface (Figure 5a). These blebs appeared early (beginning 2
to 3h post anisomycin) in the apoptosis programme and in
some cases were large (up to 5mm diameter) and contained
nuclear material (Figure 5a). Although HeLa cell apoptosis
differs in respect of membrane blebbing to that seen in
leukocytes, the blebbing noted within our studies equates to
the second wave of HeLa cell blebbing that is similar to that
seen in leukocytes.
31 However, it is unclear if the observed
blebsarereleased.Inordertoassessthenifsuchrelocationof
ICAM-3 occurs in our leukocyte model of apoptosis and to
extend our observations to assess if these visualised blebs
are released from dying cells, wild-type (WT) or ICAM-3-
deﬁcient Mutu cells were induced to apoptosis and culture
supernatants harvested. Using centrifugation to enrich for
microparticles and western blotting to detect ICAM-3, our
data indicate a clear release of ICAM-3 in microparticles
(Figure 5b).
Microparticle release from dying B cells has been reported
and is accompanied by loss of cell-surface molecules, and
those particles are reported to be chemoattractive for
macrophages.
24 More recently, microparticles from Mutu BL
cells have been noted to have chemoattractive capacity to
recruit macrophages to sitesof cell death in a manner, at least
partly, dependent upon the chemokine CX3CL1 and its
receptor CX3CR1.
25
Given that cell recruitment often requires a chemokine and
adhesion molecule to affect cell recruitment, and that we have
here shown that ICAM-3 functions to tether dying cells to
phagocytes,we reasonedthatICAM-3 isa possible candidate
adhesion molecule involved in microparticle interaction with
macrophages, thus mediating chemoattraction. To assess
Figure 3 Tethering (binding) of apoptotic cells to human or mouse phagocytes
is reduced in the absence of apoptotic cell ICAM-3. BL and Jurkat cells (WT or
ICAM-3 deﬁcient) were induced to apoptosis by UV (Mutu: 100mJ/cm
2; Jurkat
150mJ/cm
2). The capacity of THP-1 phagocytes to tether apoptotic cells (WT,
grey bars; ICAM-3-deﬁcient, open bars) was assessed at room temperature
(nonpermissive for phagocytosis) and compared with interaction (binding and
phagocytosis),whichwasassessedat371C(a).SimilartetheringassaysusingJ774
and RAW mouse phagocytes are shown (b). Data shown are mean±S.D. of
replicate samples (n¼4) from one experiment of at least three similar. **Po0.01;
***Po0.001 ANOVA with Tukey’s post-hoc test
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Cell Death and Differentiationthis, microparticles from BL cells (WT or deﬁcient for ICAM-3)
were tested for their chemoattractive capacity in a micro-
Boyden chamber. Our data revealed a potential for micro-
particles from BL cells WT for ICAM-3 to promote phagocyte
movement (Figure 6a). Interestingly, microparticles released
from ICAM-3-deﬁcient BL cells were signiﬁcantly less potent,
suggesting a major role for ICAM-3 in this process. In order to
address the possibility that microparticles from ICAM-3-
replete cells were simply promoting chemokinesis rather than
directional movement (chemotaxis), phagocytes were
exposed to microparticles without a gradient (i.e., micro-
particles were present in both wells of the chamber). In this
case, phagocyte movement was signiﬁcantly reduced
(Figure 6b), suggesting a gradient was necessary to elicit
movement of phagocytes, and conﬁrms the chemoattractive
potential of microparticles from ICAM-3-replete cells. One
Figure 4 Cell-surface ICAM-3 levels reduce during apoptosis in line with a loss of cell volume. (a) Electronic volume versus side scatter ﬂow cytometric dot plots
of Mutu BL cells at 0h (left) or 24h (right) post UV. Region 1 cells are necrotic and late apoptotic whereas region 2 cells are live or early apoptotic. (b) Mutu BL cells or
Bcl-2-transfected counterparts (Mutu/bcl-2) were irradiated with UV (100mJ/cm
2) and 4h post UV were assessed in parallel for PS exposure (using AxV-FITC staining)
and ICAM-3 expression (using direct immunoﬂuorescence with anti-ICAM-3-PE) of cells within zone 2 (live/early apoptotic cells). Grey proﬁles show staining of irradiated
cells whereas clear proﬁles show nonirradiated cells. UV-treated Mutu but not Mutu/bcl2 cells show high level of PS exposure and reduced levels of ICAM-3. (c) UV-induced
Mutu BL stained for both ICAM-3 expression (ICAM-3-PE) and PS exposure (AxV-FITC) shows PS-exposing cells (in region 2 – live/early apoptotic) preferentially express
reduced ICAM-3. (d) HeLa cells expressing ICAM-3–GFP were assessed for cell volume and ICAM-3–GFP expression over time following induction to apoptosis with
anisomycin (5mg/ml). (e) Mutu BL cells were induced to apoptosis with UV and the percentage of cells positive for ICAM-3 (assessed using anti-ICAM-3-PE and ﬂow
cytometry) was compared with cell volume (electronic volume (EV)) and PS exposure (AxV). Data shown are collected from at least 5000 events and are representative of
at least three similar experiments
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Cell Death and Differentiationsimple explanation of these results may be that cells WT for
ICAM-3 died more quickly or to a greater extent, and thus were
likely to generate more microparticles. Our studies indicated
that the kinetics and extent of death within these two cell lines
were equivalent. In order to assess generation of microparti-
cles, supernatants from apoptotic cultures of WT or ICAM-3-
deﬁcient cells, as used in the chemoattraction assays, were
analysed by dynamic light scattering using a Zetasizer
(Malvern Instruments, Malvern, UK). Such analyses measure
particle diameter and our studies indicated no signiﬁcant
difference between the generated microparticles, with both
cultures showing similar numbers and size distribution of the
particles (WT: 186±26.2nm; ICAM-3 deﬁcient: 206±
47.7nm). Taken together, these data suggest that ICAM-3 in
microparticles supports phagocyte chemoattraction.
Discussion
Herein we further characterise the role of ICAM-3, an
established mediator of apoptotic cell clearance,
17 in mediat-
ing this complex, multistage process that comprises, in vitro,
recognition (to enable speciﬁc identiﬁcation of dying cells),
binding/tethering (a strong cell–cell interaction), phagocyte
signalling (to initiate the next phase of the process),
phagocytosis (reorganisation of cytoskeleton and mem-
brane for uptake) and ﬁnally degradation. In vivo, however,
it may be necessary for phagocytes to seek dying cells
and here we consider the role of ICAM-3 within the whole
clearance process.
Here we report a novel mAb, MA4, that reacts with domains
1 and 2 of ICAM-3 and blocks interaction of apoptotic
leukocyteswithmacrophages.Inaddition,wehavedeveloped
cell lines deﬁcient for ICAM-3 expression. The capacity of
theseICAM-3-deﬁcientcells,whenapoptotic,forclearanceby
macrophages is reduced compared with their ICAM-3-replete
counterparts and provides another powerful tool for ICAM-3
analysis. These ICAM-3-deﬁcient cells complement pre-
viously described overexpression studies in HEK-293 cells
where exogenous ICAM-3 expression promotes apoptotic cell
clearance.
17 Using these tools we demonstrate that ICAM-3
promotes apoptotic cell clearance by, at least minimally,
tethering cell corpses to phagocytes. However, a role for
ICAM-3 in mediating phagocytosis cannot be ruled out.
Apoptotic cell clearance has been suggested to occur
through the development of a complex phagocytic synapse
between phagocytes and dying cells,
1 which is conceptually
similar to the ICAM-3-containing immune synapse between
T cells and antigen-presenting cells. This synapse also
shares similarities with the sequential development of cell–
cell interactions required for efﬁcient leukocyte–endothelial
cell interaction before extravasation; here, weak interactions
Figure 5 ICAM-3 is present in apoptotic blebs during zeiosis and is released
from apoptotic cells in microparticles. (a) HeLa cells transfected with ICAM-3–GFP
were imaged using epiﬂuorescence microscopy following apoptosis induction with
anisomycin (5mg/ml). Cell nuclei were stained with DAPI (250ng/ml) and optical
sections photographed and deconvoluted with Volocity software (PerkinElmer).
Images shown are noninduced and 3h post anisomycin. Images were selected
to demonstrate the location of ICAM-3. Apoptotic cells expressing high levels of
ICAM-3–GFP are shown to clearly reveal the location of ICAM-3 on blebs.
Quantitative data relating to ICAM-3 expression are provided in Figure 4. (b) Mutu
BL cells (WT or ICAM-3 deﬁcient) were UV induced to apoptosis and 16h post-UV
culture supernatants harvested. Cell bodies were removed and discarded following
low-speed centrifugation (7min; 350 g) and remaining microparticles puriﬁed
through high-speed centrifugation. Pelleted microparticles were prepared and
separated by PAGE and a western blot probed with anti-ICAM-3 mAb MA4.
Scale bar¼16mm
Figure 6 Microparticles from apoptotic cells mediate macrophage chemoat-
traction in an ICAM-3-dependent manner. Microparticles were prepared from
cultures of apoptotic Mutu BL cells (WT or ICAM-3 deﬁcient) at 16h post UV.
Supernatants were centrifuged to remove cell bodies (7min; 350 g) and used
neat. (a) Chemotaxis assay: the bottom chamber contained microparticles whereas
the top chamber contained dihydroxyvitamin D3-stimulated THP-1 cells. Migration
was allowed to proceed for 4h before staining of migrated cells and quantitation by
light microscopy. For each experimental treatment, four replicate wells were used
and within each ﬁve high-power ﬁelds (HPFs) of view counted to quantify the
numberofmigratedcells.Datashownaremean±S.E.ofindependentexperiments
(n¼7). *Po0.05 ANOVA with Tukey’s post-hoc test. (b) Chemokinesis control
where the chemotactic gradient was disrupted via inclusion of microparticles in both
upper and lower chambers. Data shown are mean±S.E. of independent
experiments (n¼4). *Po0.05 ANOVA with Tukey’s post-hoc test
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Cell Death and Differentiationlead, via signalling events, to more stable interactions utilising
b2-integrins that arrest leukocytes on vascular walls through
interaction with adhesion molecules including IgSF members.
Such comparisons may be of signiﬁcant relevance when
describing the nature of the apoptotic cell–phagocyte inter-
action process, especially with a focus on ICAM-3, a further
IgSF member that is leukocyte restricted.
The demonstration that ICAM-3 functions, on the apoptotic
cell, as an adhesion molecule promoting the tethering of
apoptotic leukocytes in a manner that is at least partially
nonredundant is novel and expands our knowledge as to the
involvement of the IgSF in this clearance process. Further-
more, it may provide useful evidence for the identiﬁcation of
the speciﬁc receptor that may be involved in the recognition of
apoptotic cell-associated ICAM-3, a receptor that to date has
proved elusive.
An intriguing aspect to ICAM-3 is its reduction in expression
during apoptosis despite its novel tethering role in clearance.
17
We show that this reduction in ICAM-3 is rapid and extensive.
Apoptosis-associated disruption/masking of epitopes through
molecular associations (e.g., ICAM-3 associations with itself or
other molecules) or molecular changes (e.g., alterations in
glycosylation) could reveal apparent reductions in ICAM-3 via
mAb-based detection. Furthermore, shedding of ICAM-3
extracellular domains as a soluble cleavage product or release
in apoptotic bodies may explain such observations. Here we
used ICAM-3–GFP to monitor ICAM-3 directly and demon-
strate in transfected HeLa cells that ICAM-3 is present within
surface blebs during apoptosis. This experimental system with
exogenous expression of a tagged ICAM-3 within HeLa cells
demonstrated that an intracellular GFP tag did not disrupt the
ability of ICAM-3 to function as a tethering ligand on apoptotic
cells. Notably, although overexpression may increase the
removal of apoptotic non-leukocytes (HEK cells),
17 it some-
times failed to increase tethering to phagocytes but simply
introduced a new tethering mechanism, now inhibitable with
anti-ICAM-3 mAb MA4.
The outcome of cell–cell interactions is dictated by the net
effect of multiple systems acting between cells, including
molecules that promote clearance and molecules that inhibit
clearance. Notably, ICAM-3 is present in both viable and
apoptotic leukocytes, although viable leukocytes are not
tethered or engulfed by phagocytes.
17 The novel role in
corpse tethering and clearance for apoptotic cell-associated
ICAM-3 is likely associated with a loss of molecules such as
CD31 and CD47 that exert inhibitory effects to prevent viable
cellclearance
18,21andmayalsoincludequalitativechangesin
ICAM-3 as cells proceed through apoptosis. Future work may
assess the potential for native ICAM-3 on viable cells to act in
an inhibitory manner similar to its close relative CD31.
Our evidence that ICAM-3 levels on leukocytes were
reduced in line with reductions in cell volume and the
observations of ICAM-3 within apoptotic ICAM-3-transfected
HeLa cell blebs led us to identify ICAM-3 within microparticles
releasedfrom apoptotic leukocytes. Such membrane loss has
been demonstrated previously and is more than a simple
phenomenon associated with poor membrane and cytoske-
letalregulationduringdeath.Itisanimportantfunctionalevent
for dying cells involved in phagocyte recruitment to undertake
the ﬁnal clearance step of the apoptosis programme.
24
Microparticles from apoptotic BL cells, as used in our studies,
have been reported to be important in monocyte recruitment
to B-cell apoptosis in a manner that is CX3CL1 (fractalkine)
dependent.
25 CX3CL1 is a novel class of chemokine with
adhesion properties, suggesting that it may play a dual role in
monocyte recruitment, acting as both chemokine and adhe-
sion molecule. Our data suggest that ICAM-3, a classical
adhesion molecule, may also function within this process as
ICAM-3-containing microparticles are signiﬁcantly more
potent in recruiting macrophages than their ICAM-3-deﬁcient
counterparts. Given our described role for ICAM-3 in tethering
apoptotic cells to phagocytes, the established role for ICAM-3
in stabilising T cell–APC interactions and the involvement of
other IgSF members (ICAM-1/2) in processes that require
chemokine signalling (e.g., leukocyte extravasation), we
propose that ICAM-3 may function as an adhesion molecule
to complement the role of CX3CL1 or other microparticle-
associated chemoattractants in recruiting phagocytes to sites
of B-cell death. Indeed, it is likely that a range of chemoat-
tractants are housed on and within complex microparticles
and these have been suggested to act as long-distance
mediators of attraction.
32,33
Interestingly,evidenceexistsforpreferentiallossofICAM-3
(54% reduction) over CD31 (18% reduction) in apoptotic
neutrophils (which lose relatively little membrane during
apoptosis relative to lymphocytes), suggesting ICAM-3 may
be preferentially released in microparticles.
34 Our work
suggests this may be an active mechanism to recruit
macrophages. Further work is also needed to assess the
immunomodulatory effect of ICAM-3 and microparticles
released from apoptotic cells. Our current work indicates that
microparticles can exert anti-inﬂammatory effects on macro-
phages irrespective of their ICAM-3 expression, although
preliminary data suggest that ICAM-3-replete microparticles
may more rapidly exert their effect, perhaps through more
efﬁcient interaction of microparticles with phagocytes.
Our work raises the possibility that ICAM-3 may be targeted
to modulate macrophage/monocyte recruitment to sites
where leukocyte cell death may be occurring. The athero-
sclerotic plaque, a nonresolving inﬂammatory site, comprises
a complex scenario of monocyte recruitment, overwhelmed
capacity for phagocytic removal of lipid-laden apoptotic
(‘foam’) cells coupled with further cell death and further
recruitment in a progressive and deleterious pathological
manner.
35 Although one might expect ICAM-3 to be involved
in monocyte recruitment to apoptotic foam cells, with
monocytes expressing ICAM-3, it is perhaps even more
compelling given the observations that foam cells express
CX3CL1,
36 and monocyte subsets in mice that accumulate in
plaques express and utilise CX3CR1 in their recruitment.
37
Furthermore, it has recently been hypothesised that apoptotic
cell-derived chemoattractants may recruit monocytes to
tumours where as tumour-associated macrophages they play
an important role in driving tumourigenesis.
33 This model
may be of great importance in the case of non-Hodgkin’s
lymphoma (e.g., Burkitt’s lymphoma from where our Mutu BL
cellsderive)wherehighlevelsofapoptosisandlargenumbers
of macrophages coexist.
33
In conclusion, we demonstrate that ICAM-3 functions at
least minimally as a ligand to tether apoptotic cells to
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dant. Associated with this function is a loss of ICAM-3 during
apoptotic cell blebbing, and released ICAM-3-containing
microparticles potently recruit phagocytes via chemotaxis to
apoptotic leukocytes. Our data are consistent with ICAM-3
complementing the role of other chemoattractants (e.g.,
CX3CL1) and may function as an important adhesion
molecule within this recruitment pathway. Further work is
now needed to assess the importance of ICAM-3 in recruiting
phagocytes to sites of leukocyte cell death (e.g., athero-
sclerotic plaques and leukocyte-derived tumours) and to
characterise the exact molecular mechanisms by which it
appears to exert its effect.
Materials and Methods
Cell isolation, cell lines and culture. Anti-ICAM-3-expressing hybridoma
cells were produced by fusing spleen cells from ICAM-3/HEK transfectant
17
immunised Balb/c mice with Ag8.653 cells. All work was undertaken in accordance
with regulatory guidance. Brieﬂy, splenocytes from an immunised mouse were
fused (5:1 ratio) with myeloma cells in the presence of 50% PEG1500 (Roche,
AppliedScience,WestSussex, UK)under serum-freeconditions.Hybridomas were
cloned using limiting dilution in RPMI-1640 medium containing 2mM L-glutamine
supplemented with 10% v/v fetal calf serum (FCS; PAA, Yeovil, UK), 100IU/ml
penicillin and 100mg/ml streptomycin) and HAT selection supplement (Sigma,
Poole, UK). The anti-ICAM-3 reactivity of culture supernatants against immobilised
ICAM-3-Fc and CD14-Fc was assessed using ELISA.
Mutu I BL cells,
38 Jurkat (human T) and THP-1 (human myelomonocytic) were
cultured in RPMI-1640 medium containing 2mM L-glutamine supplemented
with 10% FCS (PAA) and 100IU/ml penicillin and 100mg/ml streptomycin).
RAW 264.7 cells (murine macrophage
39), J774 cells (murine macrophage
40),
HeLa 229 (human epithelial) and HEK-293 cells (human epithelial) cells were
cultured similarly but in DMEM (PAA) supplemented with FCS, glutamine and
antibiotics as above.
ICAM-3-deﬁcient Mutu I cells were generated by sequential ﬂuorescence-
activated cell sorting of a WT Mutu I population. Brieﬂy, cells were stained
aseptically with excess anti-ICAM-3 mAb (CAL3.10; R&D Systems, Abingdon, UK)
followed by goat anti-mouse FITC (Sigma). At least 10000 viable cells from within
the lowest 5% ﬂuorescence region were collected using ﬂuorescence-activated cell
sorting.Cellswererecoveredinculturefor1to2weeksbeforerepeatsorting.Three
rounds of ﬂow cytometric sorting were used to produce stable, non-ICAM-3-
expressing cell populations. ICAM-3 expression was assessed regularly using
indirect immunoﬂuorescence to ensure no spontaneous recovery of ICAM-3 on
ICAM-3-deﬁcient sorted populations.
Monoclonal antibody-based assays. Monoclonal antibodies were
produced as outlined above and clones of interest were further cultured and
tissue culture supernatant harvested from static cultures when cells were þ70%
apoptotic. Such tissue culture supernatants were routinely used for subsequent
analyses.
For ELISA, Nunclon Maxisorp plates (Thermo-Fisher Scientiﬁc, Loughborough,
UK) were coated overnight with sheep anti-human Fc (The Binding Site,
Birmingham, UK) at 5mg/ml in carbonate buffer (pH 9.6; Sigma). Following
washing in PBS(T) (phosphate-buffered salineþ0.05% v/v Tween-20), Fc-tagged
proteins were added at a concentration of 1mg/ml for 1h at 371C. The resultant,
oriented Fc fusions were probed with mAbs and bound mAb detected using anti-
mouse HRP (GE Healthcare, Buckinghamshire, UK) and colourimetric SigmaFAST
OPD assay (Sigma).
For western blot analysis, cells were solubilised under reducing and
denaturing conditions, separated using standard polyacrylamide gel electro-
phoresis and electroblotted to nitrocellulose (0.45mm, Schleicher & Schuell,
Dassel, Germany, supplied by Thermo-Fisher Scientiﬁc). Membranes were
blocked in 5% non-fat milk powder in TBS-tween (0.05% v/v; pH 7.2), probed
with mAbs and detected using anti-mouse HRP and ECL detection kits
(GE Healthcare).
For indirect immunoﬂuorescence, cells were incubated with excess mAb on
ice for 30min, washed twice in PBS(A)/BSA (0.5% w/v) and incubated with goat
anti-mouse FITC (1ml per 200000 cells in 100ml volume; Sigma). Stained cells
were analysed either directly or following ﬁxation in 1% w/v formaldehyde in
PBS(A) using a Beckman-Coulter Quanta SC ﬂow cytometer (Beckman Coulter,
High Wycombe, UK). Downstream ﬂow cytometric analyses and presentations
were undertaken using VenturiOne software from Applied Cytometry Systems
(Shefﬁeld, UK) or FlowJo (Treestar Inc., Ashland, OR, USA).
ProductionofrecombinanthumanCD14andICAM-3. Recombinant
humanCD14or human ICAM-3wereproducedas soluble Fcfusion proteins(fused
to CH2/CH3 domains of human IgG1).
17 DNA for the recombinant proteins was
transfected to 293 cells using standard calcium phosphate-mediated transfections.
Fc fusion proteins were puriﬁed from culture supernatants using HiTrap protein G
columns (GE Healthcare).
ICAM-3–GFP(ICAM-3withacarboxyterminalEmGFPtag)wasconstructedusing
the Vivid Colours pcDNA6.2/C-EmGFP-GW/TOPO mammalian expression vector
(Life Technologies, Paisley, UK) as per the manufacturer’s instructions, with forward
primer: 50-ATTTAAGCTTATGGCCACCATGGTACCA-30 and reverse primer:
50-TTTTGCGGCCGCTATCATTACTTGTACAGCTCG-30. The sequence of ICAM-
3–GFP was conﬁrmed by sequencing (Functional Genomics, Birmingham, UK). In
ordertoexpressICAM-3–GFPinHeLacells,DNAwastransfectedusingtheTransIT-
LT1 transfection reagent (Mirus Bio Corporation, Madison, WI, USA; supplied by
Geneﬂow, Fradley, Staffordshire, UK) as per the manufacturer’s instructions.
Apoptosis induction and quantiﬁcation. Mutu BL or Jurkat cells were
subjected to a measured dose of UV-B irradiation, using a Chromata-vue C71 light
box and UVX radiometer (UV-P Inc., Upland, CA, USA) to induce apoptosis. BL
cells received 100mJ/cm
2 whereas Jurkats received 150mJ/cm
2. For analysis of
apoptotic nuclear morphology, cells were ﬁxed in 1% formaldehyde, stained with
4,6-diamidino-2-phenylindole (DAPI, Sigma, 250ng/ml) and observed using
inverted epiﬂuorescence microscopy. For quantitative analyses, percentages of
apoptotic cells per X200 counted per sample were enumerated. HeLa cells were
induced with anisomycin (Sigma; 5mg/ml from a stock of 5mg/ml in DMSO). HeLa
cell apoptosis was assessed by analysis of nuclear morphology following staining
with DAPI and epiﬂuorescence microscopy. Photomicrography was undertaken
using a fully motorised Zeiss Axiovert 200 M ﬂuorescence microscope (Carl Zeiss
Ltd,WelwynGardenCity,Fradley,Staffordshire,UK)andHamamatsuOrcacamera
driven by Volocity (Perkin-Elmer, Cambridge, UK).
Annexin V labelling and ﬂow cytometry. Cells were stained with
annexin V-FITC (eBioscience Ltd., Hatﬁeld, UK). Brieﬂy, cells were washed and
resuspended in binding buffer (10mM HEPES pH 7.4, 150mM NaCl, 2.5mM
CaCl2) containing annexin V-FITC (1ml per 200000 cells) for 15min on ice. Cells
were washed once in binding buffer and diluted to 1ml with binding buffer and PI
added to a ﬁnal concentration of 20mg/ml. Samples were analysed immediately on
a Quanta SC ﬂow cytometer (Beckman Coulter).
Assays of phagocyte interaction with apoptotic cells. Assay of
interaction(bindingandphagocytosis)ofphagocytes(RAW,J774orTHP-1,primary
human monocyte-derived macrophages) with apoptotic cells was carried out either
on multiwell glass slides
26 or in 24-well plates as described.
29 Brieﬂy, for the slide-
based assay, apoptotic cells and phagocytes (100:1 ratio) were co-cultured for 1h
at 371C in RPMI containing 0.2% (w/v) bovine serum albumin (Sigma). Unbound
cells were removed by extensive washing and slides ﬁxed in methanol, stained with
Jenner/Giemsa (Raymond Lamb, Thermo-Fisher Scientiﬁc) and mounted in DePeX
(VWR, Lutterworth, UK) before examination by light microscopy. Assays were
performedsimilarlyin24-wellplatesbutattheendoftheprocedure,cellswereﬁxed
in 1% formaldehyde and stained with DiffQuick II (Medion Diagnostics GmbH,
Dudingen, Switzerland). In all cases, at least 200 macrophages were assessed in
each of at least triplicate wells. As appropriate, antibodies were included in a 1:10
dilution of tissue culture supernatant. For assay of binding/tethering, co-cultures
were carried out at room temperature (201C). Data are presented as percent
macrophage binding/tethering or interacting with apoptotic cells.
Where THP-1 cells were used as the phagocyte source, cells were cultured for
72h in the presence of dihydroxyvitamin D3 (Enzo Life Sciences, Exeter, UK,
100nM) and/or phorbol-12-myristate-13-acetate (PMA, 250nM; Sigma) in four-well
glassslides(Hendley(Essex)Ltd,Loughton,UK).Whereprimaryhumanmonocyte-
derivedmacrophageswere used, monocyteswere isolatedfrom peripheralblood of
healthyvolunteersandculturedfor7daysinthepresenceof10%autologousserum
in Iscove’s modiﬁed Dulbecco’s medium.
26
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microparticles, viable cells were resuspended at 2 10
6 viable cells/ml in
serum-free RPMI supplemented with BSA (0.1%. w/v), 2mM L-glutamine and
100IU/ml penicillin and 100mg/ml streptomycin. Following induction to apoptosis
and 16h of incubation, supernatants were harvested. To remove cell bodies,
supernatants were subject to low-speed centrifugation (7min; 350 g) and lack of
cells conﬁrmed with microscopy. Supernatants were now used in chemotaxis
assayseither neat or diluted with RPMI/BSA (0.1% w/v). To purify microparticles for
Western blot analysis, supernatants were further centrifuged (30min;14000 g).
For the chemotaxis assay, a 48-well chemotaxis chamber (Neuroprobe Inc.,
Gaithersburg, Madison, WI, USA) was used in line with the manufacturer’s
instructions. Brieﬂy, 25ml of putative chemoattractant was loaded in the lower
chamber, covered with PVP-free polycarbonate membrane (5mm pore size,
4 10
3 pores/mm
2) and 50ml( 1 10
5 cells) of phagocytes added to the upper
chamber.Cell migrationwasallowed to proceedat 371Cfor 4hbefore washingand
staining of the membrane. Migrated cells remained adherent to the membrane
(bottom side) and were counted using light microscopy. In order to expose
phagocytes to microparticles in the absence of a concentration gradient,
microparticles were included in both chambers.
Conﬂict of Interest
The authors declare no conﬂict of interest.
Acknowledgements. We are grateful to Professor Yvonne Perrie for support
in particle sizing;Steve Wells for expert technical assistance;Professor Christopher
D Gregory (Edinburgh University) for provision of BL cell lines; and Dr. David L
Simmons (Cellzome formerly of University of Oxford) for ICAM-3-Fc expression
constructs. Thanks are also to the BBSRC for funding to support EET. AD was in
receipt of a BBSRC new Investigator Award (BB/E002080/1).
1. Savill J, Dransﬁeld I, Gregory C, Haslett C. A blast from the past: clearance of apoptotic
cells regulates immune responses. Nat Rev Immunol 2002; 2: 965–975.
2. Gregory CD, Devitt A. The macrophage and the apoptotic cell: an innate immune
interaction viewed simplistically? Immunology 2004; 113: 1–14.
3. Henson PM, Hume DA. Apoptotic cell removal in development and tissue homeostasis.
Trends Immunol 2006; 27: 244–250.
4. Erwig LP, Henson PM. Clearance of apoptotic cells by phagocytes. Cell Death Differ 2008;
15: 243–250.
5. Lauber K, Blumenthal SG, Waibel M, Wesselborg S. Clearance of apoptotic cells: getting
rid of the corpses. Mol Cell 2004; 14: 277–287.
6. Peter C, Waibel M, Radu CG, Yang LV, Witte ON, Schulze-Osthoff K et al. Migration to
apoptotic‘‘ﬁnd-me’’signalsismediatedviathephagocytereceptorG2A.JBiolChem2008;
283: 5296–5305.
7. Elliott MR, Chekeni FB, Trampont PC, Lazarowski ER, Kadl A, Walk SF et al. Nucleotides
releasedbyapoptoticcellsactasaﬁnd-mesignaltopromotephagocyticclearance.Nature
2009; 461: 282–286.
8. Gregory C. Cell biology: sent by the scent of death. Nature 2009; 461: 181–182.
9. Fadok VA, Voelker DR, Campbell PA, Cohen JJ, Bratton DL, Henson PM. Exposure of
phosphatidylserine on the surface of apoptotic lymphocytes triggers speciﬁc recognition
and removal by macrophages. J Immunol 1992; 148: 2207–2216.
10. Verhoven B, Schlegel RA, Williamson P. Mechanisms of phosphatidylserine exposure,
a phagocyte recognition signal, on apoptotic T lymphocytes. J Exp Med 1995; 182:
1597–1601.
11. Fadok VA, de Cathelineau A, Daleke DL, Henson PM, Bratton DL. Loss of phos-
pholipid asymmetry and surface exposure of phosphatidylserine is required for
phagocytosis of apoptotic cells by macrophages and ﬁbroblasts. J Biol Chem 2001;
276: 1071–1077.
12. Dini L, Autuori F, Lentini A, Oliverio S, Piacentini M. The clearance of apoptotic cells
in the liver is mediated by the asialoglycoprotein receptor. FEBS Lett 1992; 296: 174–178.
13. Dini L. Recognizing death: liver phagocytosis of apoptotic cells. Eur J Histochem 2000; 44:
217–227.
14. Duvall E, Wyllie AH, Morris RG. Macrophage recognition of cells undergoing programmed
cell death (apoptosis). Immunology 1985; 56: 351–358.
15. Kagan VE, Gleiss B, Tyurina YY, Tyurin VA, Elenstrom-Magnusson C, Liu SX et al.
A role for oxidative stress in apoptosis: oxidation and externalization of phosphati-
dylserine is required for macrophage clearance of cells undergoing Fas-mediated
apoptosis. J Immunol 2002; 169: 487–499.
16. Arur S, Uche UE, Rezaul K, Fong M, Scranton V, Cowan AE et al. Annexin I is an
endogenous ligand that mediates apoptotic cell engulfment. Dev Cell 2003; 4: 587–598.
17. Moffatt OD, Devitt A, Bell ED, Simmons DL, Gregory CD. Macrophage recognition of
ICAM-3 on apoptotic leukocytes. J Immunol 1999; 162: 6800–6810.
18. Brown S, Heinisch I, Ross E, Shaw K, Buckley CD, Savill J. Apoptosis disables CD31-
mediated cell detachment from phagocytes promoting binding and engulfment. Nature
2002; 418: 200–203.
19. Vernon-Wilson EF, Aurade F, Brown SB. CD31 promotes beta1 integrin-dependent
engulfment of apoptotic Jurkat T lymphocytes opsonized for phagocytosis by ﬁbronectin.
J Leukoc Biol 2006; 79: 1260–1267.
20. Vernon-Wilson EF, Aurade F, Tian L, Rowe IC, Shipston MJ, Savill J et al. CD31 delays
phagocyte membrane repolarization to promote efﬁcient binding of apoptotic cells.
J Leukoc Biol 2007; 82: 1278–1288.
21. Gardai SJ, McPhillips KA, Frasch SC, Janssen WJ, Starefeldt A, Murphy-Ullrich JE et al.
Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-
activation of LRP on the phagocyte. Cell 2005; 123: 321–334.
22. Gardai SJ, Bratton DL, Ogden CA, Henson PM. Recognition ligands on apoptotic cells: a
perspective. J Leukoc Biol 2006; 79: 896–903.
23. Nilsson A, Oldenborg PA. CD47 promotes both phosphatidylserine-independent and
phosphatidylserine-dependent phagocytosis of apoptotic murine thymocytes by non-
activated macrophages. Biochem Biophys Res Commun 2009; 387: 58–63.
24. Segundo C, Medina F, Rodriguez C, Martinez-Palencia R, Leyva-Cobian F, Brieva JA.
Surface molecule loss and bleb formation by human germinal center B cells undergoing
apoptosis: role of apoptotic blebs in monocyte chemotaxis. Blood 1999; 94: 1012–1020.
25. Truman LA, Ford CA, Pasikowska M, Pound JD, Wilkinson SJ, Dumitriu IE et al. CX3CL1/
fractalkine is released from apoptotic lymphocytes to stimulate macrophage chemotaxis.
Blood 2008; 112: 5026–5036.
26. Devitt A, Moffatt OD, Raykundalia C, Capra JD, Simmons DL, Gregory CD. Human CD14
mediates recognition and phagocytosis of apoptotic cells. Nature 1998; 392: 505–509.
27. Devitt A, Pierce S, Oldreive C, Shingler WH, Gregory CD. CD14-dependent clearance of
apoptotic cells by human macrophages: the role of phosphatidylserine. Cell Death Differ
2003; 10: 371–382.
28. Grifﬁths HR, Willetts RS, Grant MM, Mistry N, Lunec J, Bevan RJ. In vivo vitamin C
supplementation increases phosphoinositol transfer protein expression in peripheral blood
mononuclear cells from healthy individuals. Br J Nutr 2009; 101: 1432–1439.
29. Devitt A, Parker KG, Ogden CA, Oldreive C, Clay MF, Melville LA et al. Persistence of
apoptotic cells without autoimmune disease or inﬂammation in CD14-/- mice. J Cell Biol
2004; 167: 1161–1170.
30. Dive C, Gregory CD, Phipps DJ, Evans DL, Milner AE, Wyllie AH. Analysis and
discrimination of necrosis and apoptosis (programmed cell death) by multiparameter ﬂow
cytometry. Biochim Biophys Acta 1992; 1133: 275–285.
31. Lane JD, Allan VJ, Woodman PG. Active relocation of chromatin and endoplasmic
reticulum into blebs in late apoptotic cells. J Cell Sci 2005; 118 (Pt 17): 4059–4071.
32. Mause SF, Weber C. Microparticles: protagonists of a novel communication network for
intercellular information exchange. Circ Res 2010; 107: 1047–1057.
33. Gregory CD, Pound JD. Microenvironmental inﬂuences of apoptosis in vivo and in vitro.
Apoptosis 2010; 15: 1029–1049.
34. HartSP,RossJA,RossK,HaslettC,Dransﬁeld I.Molecularcharacterizationofthesurface
of apoptotic neutrophils: implications for functional downregulation and recognition by
phagocytes. Cell Death Differ 2000; 7: 493–503.
35. Tabas I. Macrophage death and defective inﬂammation resolution in atherosclerosis. Nat
Rev Immunol 2010; 10: 36–46.
36. Barlic J, Murphy PM. Chemokine regulation of atherosclerosis. J Leukoc Biol 2007; 82:
226–236.
37. Tacke F, Alvarez D, Kaplan TJ, Jakubzick C, Spanbroek R, Llodra J et al. Monocyte
subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within
atherosclerotic plaques. J Clin Invest 2007; 117: 185–194.
38. Gregory CD, Rowe M, Rickinson AB. Different Epstein-Barr virus-B cell interactions in
phenotypically distinct clones of a Burkitt’s lymphoma cell line. J Gen Virol 1990; 71 (Pt 7):
1481–1495.
39. Raschke WC, Baird S, Ralph P, Nakoinz I. Functional macrophage cell lines transformed
by Abelson leukemia virus. Cell 1978; 15: 261–267.
40. Ralph P, Nakoinz I. Phagocytosis and cytolysis by a macrophage tumour and its cloned
cell line. Nature 1975; 257: 393–394.
This work is licensed under the Creative Commons
Attribution-NonCommercial-No Derivative Works 3.0
Unported License. To view a copy of this license, visit http://
creativecommons.org/licenses/by-nc-nd/3.0
Supplementary Information accompanies the paper on Cell Death and Differentiation website (http://www.nature.com/cdd)
Apoptotic cell ICAM-3 and clearance of apoptotic cells
EE Torr et al
679
Cell Death and Differentiation